Atherosclerosis-Pipeline Review, H1 2015

Atherosclerosis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6682IDB
  • |
  • Pages: 276
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Atherosclerosis-Pipeline Review, H1 2015


Global Markets Direct's, 'Atherosclerosis-Pipeline Review, H1 2015', provides an overview of the Atherosclerosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Atherosclerosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Atherosclerosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Atherosclerosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Atherosclerosis Overview 11

Therapeutics Development 12

Pipeline Products for Atherosclerosis-Overview 12

Pipeline Products for Atherosclerosis-Comparative Analysis 13

Atherosclerosis-Therapeutics under Development by Companies 14

Atherosclerosis-Therapeutics under Investigation by Universities/Institutes 19

Atherosclerosis-Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Atherosclerosis-Products under Development by Companies 25

Atherosclerosis-Products under Investigation by Universities/Institutes 30

Atherosclerosis-Companies Involved in Therapeutics Development 32

Ache Laboratorios Farmaceuticos S/A 32

advanceCor GmbH 33


Arisaph Pharmaceuticals, Inc. 35

Artery Therapeutics, Inc. 36

AstraZeneca Plc 37

Athera Biotechnologies AB 38

AtheroNova Inc. 39

AuraSense Therapeutics, LLC 40

Bayer AG 41

Bridge Bioresearch Plc 42

Campus Technologies Freiburg GmbH 43

Cardax Pharmaceuticals, Inc. 44

ChemoCentryx, Inc. 45

CohBar Inc. 46

DoNatur GmbH 47

Dr. Reddy's Laboratories Limited 48

Dybly AG 49

Eli Lilly and Company 50

F. Hoffmann-La Roche Ltd. 51

GenKyoTex S.A. 52

Gilead Sciences, Inc. 53

Isis Pharmaceuticals, Inc. 54

Jenrin Discovery, Inc. 55

Johnson & Johnson 56

KineMed, Inc. 57

Kowa Company, Ltd. 58

Lead Discovery Center GmbH 59

MedImmune, LLC 60

Merck & Co., Inc. 61

MI.TO. Technology S.r.L. 62

Novartis AG 63

Omeros Corporation 64

OPKO Health, Inc. 65

Otsuka Holdings Co., Ltd. 66

Provid Pharmaceuticals, Inc. 67

Resverlogix Corp. 68

The Medicines Company 69

Therapix Biosciences Ltd 70

Vascular Biogenics Ltd. 71

Vericel Corporation 72

Vitae Pharmaceuticals, Inc. 73

Atherosclerosis-Therapeutics Assessment 74

Assessment by Monotherapy Products 74

Assessment by Target 75

Assessment by Mechanism of Action 78

Assessment by Route of Administration 81

Assessment by Molecule Type 83

Drug Profiles 85

6860766-Drug Profile 85

AEM-28-Drug Profile 86

AG-01-Drug Profile 87

AHRO-001-Drug Profile 88

AHRO-002-Drug Profile 90

AHRO-003-Drug Profile 91

aliskiren fumarate-Drug Profile 92

AM-0010-Drug Profile 94

anacetrapib-Drug Profile 95

Annexin A-5-Drug Profile 97

Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis-Drug Profile 99

ARI-1778-Drug Profile 100

Artpep-2-Drug Profile 101

ATH-03-Drug Profile 102

ATH-04-Drug Profile 103

ATH-05-Drug Profile 104

ATH-06-Drug Profile 105

AZ-876-Drug Profile 106

BAY-606583-Drug Profile 107

BSN-272-Drug Profile 108

CCX-771-Drug Profile 109

CCX-872-Drug Profile 110

CDX-085-Drug Profile 111

Cell Therapy for Atherosclerosis-Drug Profile 113

CM-7-Drug Profile 114

COR-2-Drug Profile 115

CSN-501-Drug Profile 116

CVX-210H-Drug Profile 117

D-4F-Drug Profile 118

DIAS-2-Drug Profile 119

DRL-17822-Drug Profile 120

Drug for Atherosclerosis-Drug Profile 121

Drug to Agonize TLR-4 for Metabolic Disorders, Immunology and Cardiovascular Disease-Drug Profile 122

Drugs for Cardiovascular Diseases-Drug Profile 123

Drugs to Activate TLR3 for Atherosclerosis-Drug Profile 125

Drugs to Antagonize NMDA Receptor for Atherosclerosis-Drug Profile 126

DYB-186-Drug Profile 127

EP-80317-Drug Profile 128

evacetrapib-Drug Profile 129

FX-5A-Drug Profile 131

Gene Therapy for Arteriosclerosis and Endothelial Dysfunction-Drug Profile 132

Gene Therapy to Activate Interleukin 10 for Atherosclerosis-Drug Profile 133

Gene Therapy to Target miR-145 for Atherosclerosis-Drug Profile 134

GKT-136901-Drug Profile 135

GKT-137831-Drug Profile 137

GKT-901-Drug Profile 138

GYY-4137-Drug Profile 139

Humanin-Drug Profile 141

INV-88-Drug Profile 142

ISIS-APOARx-Drug Profile 143

ixmyelocel-T-Drug Profile 144

JD-6000 Series-Drug Profile 147

K-312-Drug Profile 148

K-877-Drug Profile 149

KM-011-Drug Profile 150

KRP-206-Drug Profile 151

LDN-193189-Drug Profile 152

LPC-01-Drug Profile 153

MCS-18-Drug Profile 154

MDCO-216-Drug Profile 156

MEDI-6012-Drug Profile 158

melittin-Drug Profile 160

microRNA-30c for Hyperlipidemia and Atherosclerosis-Drug Profile 161

Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases-Drug Profile 163

Monoclonal Antibody to Inhibit Endothelial Lipase for Atherosclerosis-Drug Profile 165

Nanotherapeutics-Drug Profile 166

Oligonucleotide to Agonize SRB1 for Atherosclerosis and Lymphoma-Drug Profile 167

P-16-Drug Profile 169

PC-mAb-Drug Profile 170

Peptides to Inhibit Calcineurin for Rheumatoid Arthritis and Atherosclerosis-Drug Profile 172

Protein for Atherosclerosis-Drug Profile 173

Px-102-Drug Profile 174

Recombinant Protein for Atherosclerosis and Hepatic Steatosis-Drug Profile 176

Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis-Drug Profile 178

RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis-Drug Profile 179

RO-6836191-Drug Profile 180

rPAI-123-Drug Profile 181

RVX-208-Drug Profile 182

Small Molecule for Atherosclerosis-Drug Profile 184

Small Molecule for Atherosclerosis-Drug Profile 185

Small Molecule Target GPR176 for Atherosclerosis-Drug Profile 186

Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology-Drug Profile 187

Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders-Drug Profile 188

Small Molecule to Target GPR132 for Atherosclerosis-Drug Profile 189

Small Molecules for Atherosclerosis-Drug Profile 190

Small Molecules for Atherosclerosis-Drug Profile 191

Small Molecules for Inflammatory Diseases-Drug Profile 192

Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders-Drug Profile 193

Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity-Drug Profile 195

Small Molecules to Antagonize TLR2 and TLR4 for Immune inflammatory Diseases-Drug Profile 196

Small Molecules to Inhibit Chymase for Atherosclerosis-Drug Profile 197

Small Molecules to Inhibit Lipase for Atherosclerosis-Drug Profile 198

SPX-7233801-Drug Profile 199

Stem Cell Therapy for Atherosclerosis-Drug Profile 200

SYN-20110119RU-Drug Profile 201

Synthetic Peptide for Cardiovascular, Gastrointestinal and Metabolic Disorders-Drug Profile 202

Synthetic Peptide to Inhibit F11R for Atherosclerosis-Drug Profile 204

Synthetic Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation-Drug Profile 206

Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration-Drug Profile 207

Vaccine for Atherosclerosis-Drug Profile 209

Vaccine for Atherosclerosis-Drug Profile 210

Vaccine for Atherosclerosis-Drug Profile 211

Vaccine to Target Angiotensin II for Cardiovascular Diseases-Drug Profile 212

VB-201-Drug Profile 213

VTP-4-Drug Profile 215

Atherosclerosis-Recent Pipeline Updates 216

Atherosclerosis-Dormant Projects 245

Atherosclerosis-Discontinued Products 254

Atherosclerosis-Product Development Milestones 257

Featured News & Press Releases 257

Appendix 268

Methodology 268

Coverage 268

Secondary Research 268

Primary Research 268

Expert Panel Validation 268

Contact Us 268

Disclaimer 269

List of Tables

Number of Products under Development for Atherosclerosis, H1 2015 19

Number of Products under Development for Atherosclerosis-Comparative Analysis, H1 2015 20

Number of Products under Development by Companies, H1 2015 22

Number of Products under Development by Companies, H1 2015 (Contd..1) 23

Number of Products under Development by Companies, H1 2015 (Contd..2) 24

Number of Products under Development by Companies, H1 2015 (Contd..3) 25

Number of Products under Investigation by Universities/Institutes, H1 2015 27

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 28

Comparative Analysis by Late Stage Development, H1 2015 29

Comparative Analysis by Clinical Stage Development, H1 2015 30

Comparative Analysis by Early Stage Development, H1 2015 31

Products under Development by Companies, H1 2015 32

Products under Development by Companies, H1 2015 (Contd..1) 33

Products under Development by Companies, H1 2015 (Contd..2) 34

Products under Development by Companies, H1 2015 (Contd..3) 35

Products under Development by Companies, H1 2015 (Contd..4) 36

Products under Investigation by Universities/Institutes, H1 2015 37

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 38

Atherosclerosis-Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 39

Atherosclerosis-Pipeline by advanceCor GmbH, H1 2015 40

Atherosclerosis-Pipeline by AFFiRiS AG, H1 2015 41

Atherosclerosis-Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 42

Atherosclerosis-Pipeline by Artery Therapeutics, Inc., H1 2015 43

Atherosclerosis-Pipeline by AstraZeneca Plc, H1 2015 44

Atherosclerosis-Pipeline by Athera Biotechnologies AB, H1 2015 45

Atherosclerosis-Pipeline by AtheroNova Inc., H1 2015 46

Atherosclerosis-Pipeline by AuraSense Therapeutics, LLC, H1 2015 47

Atherosclerosis-Pipeline by Bayer AG, H1 2015 48

Atherosclerosis-Pipeline by Bridge Bioresearch Plc, H1 2015 49

Atherosclerosis-Pipeline by Campus Technologies Freiburg GmbH, H1 2015 50

Atherosclerosis-Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 51

Atherosclerosis-Pipeline by ChemoCentryx, Inc., H1 2015 52

Atherosclerosis-Pipeline by CohBar Inc., H1 2015 53

Atherosclerosis-Pipeline by DoNatur GmbH, H1 2015 54

Atherosclerosis-Pipeline by Dr. Reddy's Laboratories Limited, H1 2015 55

Atherosclerosis-Pipeline by Dybly AG, H1 2015 56

Atherosclerosis-Pipeline by Eli Lilly and Company, H1 2015 57

Atherosclerosis-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 58

Atherosclerosis-Pipeline by GenKyoTex S.A., H1 2015 59

Atherosclerosis-Pipeline by Gilead Sciences, Inc., H1 2015 60

Atherosclerosis-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 61

Atherosclerosis-Pipeline by Jenrin Discovery, Inc., H1 2015 62

Atherosclerosis-Pipeline by Johnson & Johnson, H1 2015 63

Atherosclerosis-Pipeline by KineMed, Inc., H1 2015 64

Atherosclerosis-Pipeline by Kowa Company, Ltd., H1 2015 65

Atherosclerosis-Pipeline by Lead Discovery Center GmbH, H1 2015 66

Atherosclerosis-Pipeline by MedImmune, LLC, H1 2015 67

Atherosclerosis-Pipeline by Merck & Co., Inc., H1 2015 68

Atherosclerosis-Pipeline by MI.TO. Technology S.r.L., H1 2015 69

Atherosclerosis-Pipeline by Novartis AG, H1 2015 70

Atherosclerosis-Pipeline by Omeros Corporation, H1 2015 71

Atherosclerosis-Pipeline by OPKO Health, Inc., H1 2015 72

Atherosclerosis-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 73

Atherosclerosis-Pipeline by Provid Pharmaceuticals, Inc., H1 2015 74

Atherosclerosis-Pipeline by Resverlogix Corp., H1 2015 75

Atherosclerosis-Pipeline by The Medicines Company, H1 2015 76

Atherosclerosis-Pipeline by Therapix Biosciences Ltd, H1 2015 77

Atherosclerosis-Pipeline by Vascular Biogenics Ltd., H1 2015 78

Atherosclerosis-Pipeline by Vericel Corporation, H1 2015 79

Atherosclerosis-Pipeline by Vitae Pharmaceuticals, Inc., H1 2015 80

Assessment by Monotherapy Products, H1 2015 81

Number of Products by Stage and Target, H1 2015 83

Number of Products by Stage and Mechanism of Action, H1 2015 86

Number of Products by Stage and Route of Administration, H1 2015 89

Number of Products by Stage and Molecule Type, H1 2015 91

Atherosclerosis Therapeutics-Recent Pipeline Updates, H1 2015 223

Atherosclerosis-Dormant Projects, H1 2015 252

Atherosclerosis-Dormant Projects (Contd..1), H1 2015 253

Atherosclerosis-Dormant Projects (Contd..2), H1 2015 254

Atherosclerosis-Dormant Projects (Contd..3), H1 2015 255

Atherosclerosis-Dormant Projects (Contd..4), H1 2015 256

Atherosclerosis-Dormant Projects (Contd..5), H1 2015 257

Atherosclerosis-Dormant Projects (Contd..6), H1 2015 258

Atherosclerosis-Dormant Projects (Contd..7), H1 2015 259

Atherosclerosis-Dormant Projects (Contd..8), H1 2015 260

Atherosclerosis-Discontinued Products, H1 2015 261

Atherosclerosis-Discontinued Products (Contd..1), H1 2015 262

Atherosclerosis-Discontinued Products (Contd..2), H1 2015 263

List of Figures

Number of Products under Development for Atherosclerosis, H1 2015 19

Number of Products under Development for Atherosclerosis-Comparative Analysis, H1 2015 20

Number of Products under Development by Companies, H1 2015 21

Number of Products under Investigation by Universities/Institutes, H1 2015 26

Comparative Analysis by Clinical Stage Development, H1 2015 30

Comparative Analysis by Early Stage Products, H1 2015 31

Assessment by Monotherapy Products, H1 2015 81

Number of Products by Top 10 Targets, H1 2015 82

Number of Products by Stage and Top 10 Targets, H1 2015 82

Number of Products by Top 10 Mechanism of Actions, H1 2015 85

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 85

Number of Products by Top 10 Routes of Administration, H1 2015 88

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 88

Number of Products by Top 10 Molecule Types, H1 2015 90

Number of Products by Stage and Top 10 Molecule Types, H1 2015 90

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Ache Laboratorios Farmaceuticos

advanceCor GmbH


Arisaph Pharmaceuticals, Inc.

Artery Therapeutics, Inc.

AstraZeneca Plc

Athera Biotechnologies AB

AtheroNova Inc.

AuraSense Therapeutics, LLC

Bayer AG

Bridge Bioresearch Plc

Campus Technologies Freiburg G

Cardax Pharmaceuticals, Inc.

ChemoCentryx, Inc.

CohBar Inc.

DoNatur GmbH

Dr. Reddy's Laboratories Limited

Dybly AG

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

GenKyoTex S.A.

Gilead Sciences, Inc.

Isis Pharmaceuticals, Inc.

Jenrin Discovery, Inc.

Johnson & Johnson

KineMed, Inc.

Kowa Company, Ltd.

Lead Discovery Center GmbH

MedImmune, LLC

Merck & Co., Inc.

MI.TO. Technology S.r.L.

Novartis AG

Omeros Corporation

OPKO Health, Inc.

Otsuka Holdings Co., Ltd.

Provid Pharmaceuticals, Inc.

Resverlogix Corp.

The Medicines Company

Therapix Biosciences Ltd

Vascular Biogenics Ltd.

Vericel Corporation

Vitae Pharmaceuticals, Inc.

Atherosclerosis Therapeutic Products under Development, Key Players in Atherosclerosis Therapeutics, Atherosclerosis Pipeline Overview, Atherosclerosis Pipeline, Atherosclerosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 136140
Site License
USD 4000 INR 272280
Corporate User License
USD 6000 INR 408420



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]